Phathom Pharmaceuticals (PHAT) Total Non-Current Liabilities (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Total Non-Current Liabilities data on file, last reported at $638.6 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $638.6 million, up 2.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $638.6 million (up 2.82% YoY), and the FY2025 annual result was $693.3 million, up 11.75% from the prior year.
• Total Non-Current Liabilities retreated to $638.6 million in Q1 2026 per PHAT's latest filing, from $693.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $693.3 million in Q4 2025 and troughed at $103.5 million in Q1 2022.
• A 5-year average of $437.1 million and a median of $495.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities jumped 171.94% in 2022, then increased 2.82% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $232.1 million in 2022, then surged by 105.45% to $476.9 million in 2023, then soared by 30.09% to $620.4 million in 2024, then grew by 11.75% to $693.3 million in 2025, then dropped by 7.9% to $638.6 million in 2026.
• Business Quant data shows PHAT's Total Non-Current Liabilities at $638.6 million in Q1 2026, $693.3 million in Q4 2025, and $651.3 million in Q3 2025.